A Novel Signature Based on m6A Regulator‐Mediated Genes Along Glycolytic Pathway Predicts Prognosis and Immunotherapy Responses of Gastric Cancer Patients

Authors:
Publisher website
Google Scholar
Abstract
N6‐methyladenosine (m6A) modification is involved in many aspects of gastric cancer (GC). Moreover, m6A and glycolysis‐related genes (GRGs) play important roles in immunotherapeutic and prognostic implication of GC. However, GRGs involved in m6A regulation have never been analyzed comprehensively in GC. Herein, the study aims to identify and validate a novel signature based on m6A‐related GRGs in GC patients. Therefore, a m6A‐related GRGs signature is established, which can predict the survival of patients with GC and remain an independent prognostic factor in multivariate analyses. Clinical significance of the model is well validated in internal cohort and independent validation cohort. In addition, the expression levels of risk model‐related GRGs in clinical samples are validated. Consistent with the database results, all model genes are up‐regulated in expression except DCN. After regrouping the patients based on this risk model, the study can effectively distinguish between them in respect to immune‐cell infiltration microenvironment and immunotherapeutic response. Additionally, candidate drugs targeting risk model‐related GRGs are confirmed. Finally, a nomogram combining risk scores and clinical parameters is created, and calibration plots show that the nomogram can accurately predict survival. This risk model can serve as a reliable assessment tool for predicting prognosis and immunotherapeutic responses in GC patients.
Funding Information
  • National Natural Science Foundation of China (82272409, 31970728)

This publication has 51 references indexed in Scilit: